In recent trading session, Cartesian Therapeutics Inc (NASDAQ:RNAC) saw 1.19 million shares changing hands at last check today with its beta currently measuring 0.74. Company’s recent per share price level of $1.10 trading at $0.05 or 4.77% at last check today assigns it a market valuation of $170.74M. That most recent trading price of RNAC’s stock is at a discount of -80.91% from its 52-week high price of $1.99 and is indicating a premium of 28.18% from its 52-week low price of $0.79. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.82 million shares which gives us an average trading volume of 664.11K if we extend that period to 3-months.
For Cartesian Therapeutics Inc (RNAC), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.07 in the current quarter.
Cartesian Therapeutics Inc (NASDAQ:RNAC) trade information
Upright in the green today for gaining 4.77%, in the last five days RNAC remained trading in the green while hitting it’s week-highest on Friday, 11/17/23 when the stock touched $1.10 price level, adding 2.65% to its value on the day. Cartesian Therapeutics Inc’s shares saw a change of -2.65% in year-to-date performance and have moved 14.86% in past 5-day. Cartesian Therapeutics Inc (NASDAQ:RNAC) showed a performance of -1.78% in past 30-days. Number of shares sold short was 7.98 million shares which calculate 17.12 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $3.25 to the stock, which implies a rise of 66.15% to its recent value today. Analysts have been projecting $1.00 as a low price target for the stock while placing it at a high target of $5.00. It follows that stock’s current price would drop -354.55% in reaching the projected high whereas dropping to the targeted low would mean a gain of 9.09% for stock’s current value.
Cartesian Therapeutics Inc (RNAC) estimates and forecasts
Statistics highlight that Cartesian Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -3.50% of value to its shares in past 6 months, showing an annual growth rate of -350.00% while that of industry is 14.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to decrease by -275.00% in the current quarter and calculating 42.90% increase in the next quarter. This year revenue growth is estimated to fall -75.70% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $5.37 million for the same. And 2 analysts are in estimates of company making revenue of $5 million in the next quarter that will end on Mar 2024. Company posted $16.8 million and $5.94 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -68.00% while estimating it to be -15.80% for the next quarter.
Cartesian Therapeutics Inc is more likely to be releasing its next quarterly report on November 13 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Cartesian Therapeutics Inc (NASDAQ:RNAC)’s Major holders
Insiders are in possession of 25.06% of company’s total shares while institution are holding 47.78 percent of that, with stock having share float percentage of 63.75%. Investors also watch the number of corporate investors in a company very closely, which is 47.78% institutions for Cartesian Therapeutics Inc that are currently holding shares of the company.